Tezepelumab and Methacholine Airway Hyperresponsiveness in Participants With Mild Allergic Asthma
Status:
Not yet recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
Asthma is a condition where small inhaled particles can cause inflammation in the lung
leading to constriction of airways and wheeze. Mast cells are immune cells in airways that
can release chemical causing constriction of the airways and wheeze. Tezepelumab is an
injectable medication that improves asthma by stopping inflammation, but the effect on mast
cells is not known. Tezepelumab was approved in Canada July 2022 for treatment of severe
asthma. Tezepelumab is not approved for treatment of mild asthma by any health authority,
except for use in research studies like this. This study will examine the effect of
tezepelumab on mast cells and airway constriction to understand the mechanisms of asthma, and
which patients will benefit most from drugs like tezepelumab.